公开(公告)号：US20240342453A1

公开(公告)日：2024-10-17

申请号：US18518280

申请日：2023-11-22

申请人： Corium Pharma Solutions, Inc.

发明人： Parminder Singh ,  Robert Wade Worsham ,  Joseph C. Trautman ,  Danir Bayramov ,  Danny Lee Bowers ,  Andrew Richard Klemm ,  Steven Richard Klemm ,  Guohua Chen

IPC分类号： A61M37/00 ,  A61K9/00 ,  A61K38/29 ,  A61K38/38 ,  A61M5/32

CPC分类号： A61M37/0015 ,  A61K9/0021 ,  A61K38/29 ,  A61K38/385 ,  A61M5/3298 ,  A61M2037/0046 ,  A61M2037/0053 ,  A61M2037/0061 ,  A61M2202/0007 ,  A61M2202/07 ,  A61M2202/30 ,  A61M2207/00

摘要： In an aspect of the invention, an array of microprotrusions is formed by providing a mold with cavities corresponding to the negative of the microprotrusions, casting atop the mold a first solution comprising a biocompatible material and a solvent, removing the solvent, casting a second solution atop the first cast solution, removing the solvent from the second solution, and demolding the resulting array from the mold. The first solution preferably contains an active ingredient.

公开(公告)号：US20240342252A1

公开(公告)日：2024-10-17

申请号：US18438207

申请日：2024-02-09

申请人： Radius Health, Inc.

发明人： Matt Burke ,  Silvio Campagna

IPC分类号： A61K38/29 ,  C07K1/04 ,  C07K1/06 ,  C07K1/08 ,  C07K14/635

CPC分类号： A61K38/29 ,  C07K1/066 ,  C07K14/635 ,  C07K1/04 ,  C07K1/06 ,  C07K1/084

摘要： Disclosed herein is an improved process for preparing abaloparatide. The process generally utilizes solid phase peptide synthesis employing an Fmoc-protection scheme. Incorporating a systematic recoupling step of a glutamine residue (Gln16) has been found to minimize the formation of an undesirable des-Gln16 abaloparatide impurity, which is often obtained in significant quantities in the conventional process.

公开(公告)号：US12076373B2

公开(公告)日：2024-09-03

申请号：US16724400

申请日：2019-12-23

申请人： Entera Bio Ltd.

发明人： Gregory Burshtein ,  Ariel Rothner ,  Phillip M. Schwartz ,  Hillel Galitzer

IPC分类号： A61K38/29 ,  A61K9/00 ,  A61K9/20 ,  A61K9/28 ,  A61K31/05 ,  A61K31/166 ,  A61K31/19 ,  A61K31/195 ,  A61K31/20 ,  A61K38/22 ,  A61K38/55 ,  A61K47/12 ,  A61P5/18 ,  A61P19/10 ,  A61K45/06

CPC分类号： A61K38/29 ,  A61K9/0053 ,  A61K9/20 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/2086 ,  A61K9/28 ,  A61K9/2886 ,  A61K31/05 ,  A61K31/166 ,  A61K31/19 ,  A61K31/20 ,  A61K38/22 ,  A61K38/55 ,  A61K47/12 ,  A61P5/18 ,  A61P19/10 ,  A61K45/06 ,  A61K2300/00 ,  A61K38/55 ,  A61K2300/00 ,  A61K38/29 ,  A61K2300/00

摘要： A pharmaceutical composition for oral administration is disclosed herein, comprising a therapeutically active agent, SNAC and at least one antacid compound. Further disclosed herein is a pharmaceutical composition unit dosage form for oral administration of a therapeutically active agent is provided herein, the unit dosage form comprising: a core comprising the therapeutically active agent and SNAC (sodium 8-N-(2-hydroxybenzoyl)aminocaprylate); and an external layer comprising at least one protective agent selected from the group consisting of an antacid compound and a protease inhibitor. Methods and uses utilizing the aforementioned pharmaceutical compositions, as well as methods and uses utilizing co-administration, by oral administration, of at least one antacid composition, and a composition comprising the therapeutically active agent and SNAC, are further disclosed herein, for use in treating a condition treatable by oral administration of the therapeutically active agent.

公开(公告)号：US20240238415A1

公开(公告)日：2024-07-18

申请号：US18559261

申请日：2022-05-04

申请人： Baylor College of Medicine

发明人： Brendan LEE

IPC分类号： A61K39/395 ,  A61K31/663 ,  A61K38/23 ,  A61K38/29 ,  A61K47/64 ,  A61P19/08 ,  C07K16/22

CPC分类号： A61K39/3955 ,  A61K31/663 ,  A61K38/23 ,  A61K38/29 ,  A61K47/645 ,  A61P19/08 ,  C07K16/22 ,  C07K2317/21

摘要： The present disclosure provides methods for treating and improving moderate-to-severe osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of an agent that binds and neutralizes transforming growth factor beta (TGFβ).

公开(公告)号：US20240082488A1

公开(公告)日：2024-03-14

申请号：US18481857

申请日：2023-10-05

申请人： Rani Therapeutics, LLC

发明人： Mir IMRAN ,  Peter HERRMANN ,  Baber SYED ,  Timothy H. WILLIAMS ,  Chang Jin ONG ,  Greg METHOD

IPC分类号： A61M5/155 ,  A61K38/13 ,  A61K38/21 ,  A61K38/26 ,  A61K38/27 ,  A61K38/28 ,  A61K38/29 ,  A61K38/30 ,  A61K38/55 ,  A61M5/142 ,  A61M31/00

CPC分类号： A61M5/155 ,  A61K38/13 ,  A61K38/21 ,  A61K38/26 ,  A61K38/27 ,  A61K38/28 ,  A61K38/29 ,  A61K38/30 ,  A61K38/55 ,  A61M5/14244 ,  A61M31/002 ,  A61K9/4808

摘要： Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade within the wall to release the drug to produce a therapeutic effect. The preparation can be coupled to a delivery mechanism having one or more balloons or other expandable devices which are expandable responsive to a condition in the small intestine or other GI lumen to advance the preparation out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

公开(公告)号：US20230381284A1

公开(公告)日：2023-11-30

申请号：US18355223

申请日：2023-07-19

申请人： ASCENDIS PHARMA BONE DISEASES A/S

发明人： Kennett Sprogøe ,  Felix Cleemann ,  Guillaume Maitro ,  Mathias Krusch ,  Thomas Wegge ,  Joachim Zettler

IPC分类号： A61K38/29 ,  A61K9/00 ,  A61K9/16 ,  A61K47/60 ,  A61K47/54

CPC分类号： A61K38/29 ,  A61K9/0019 ,  A61K9/1647 ,  A61K47/60 ,  A61K47/545 ,  A61K47/54 ,  A61K47/34

摘要： The present invention relates to a pharmaceutical composition comprising at least one controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment, control, delay or prevention of a condition that can be treated, controlled, delayed or prevented with PTH, pharmaceutical composition comprising at least one controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment, control, delay or prevention of a condition that can be treated, controlled, delayed or prevented with PTH, wherein said pharmaceutical composition is administered no more frequent than once every 24 hours with a dosage of the controlled-release PTH compound that corresponds to no more than 70% of the molar equivalent dose of PTH 1-84 administered every 24 hours required to maintain serum calcium within normal levels over said 24 hour period in humans.

公开(公告)号：US20230364263A1

公开(公告)日：2023-11-16

申请号：US18302962

申请日：2023-04-19

申请人： Salk Institute for Biological Studies

发明人： Clodagh O'Shea ,  Colin Powers ,  Lei Zhang

IPC分类号： A61K48/00 ,  A61P19/08 ,  A61K38/18 ,  A61K38/29 ,  A61K38/30 ,  C07K14/005 ,  C12N9/02 ,  C12N9/12 ,  C12N15/86

CPC分类号： A61K48/0041 ,  A61P19/08 ,  A61K38/1875 ,  A61K38/29 ,  A61K38/30 ,  A61K48/0058 ,  C07K14/005 ,  C12N9/0069 ,  C12N9/1241 ,  C12N15/86 ,  C12Y113/12007 ,  C07K2319/33 ,  C12N2710/10322 ,  C12N2710/10345

摘要： Synthetic adenoviruses with tropism to bone tissue are described. The synthetic adenoviruses include an adenovirus type 11 (Ad11) fiber protein or a chimeric adenovirus fiber protein having an Ad11 knob domain. The synthetic adenoviruses can also include a transgene, such as a reporter gene or a transgene encoding a factor that promotes bone regeneration or repair. Use of the synthetic adenoviruses to target bone tissue and/or to promote bone repair or regeneration is also described.

公开(公告)号：US11793861B2

公开(公告)日：2023-10-24

申请号：US18053693

申请日：2022-11-08

申请人： ASCENDIS PHARMA BONE DISEASES A/S

发明人： Kennett Sprogøe ,  Felix Cleemann ,  Guillaume Maitro ,  Mathias Krusch ,  Thomas Wegge ,  Joachim Zettler

IPC分类号： A61K38/29 ,  A61K47/54 ,  A61K47/60 ,  A61K9/00

CPC分类号： A61K38/29 ,  A61K9/0019 ,  A61K47/54 ,  A61K47/545 ,  A61K47/60

摘要： The present invention relates to PTH prodrugs, pharmaceutical compositions comprising such PTH prodrugs and their uses.

公开(公告)号：US20230330116A1

公开(公告)日：2023-10-19

申请号：US18192696

申请日：2023-03-30

申请人： Indiana University Research and Technology Corporation ,  University of Rochester ,  The United States of America As Represented by the Department of Veterans Affairs Office of General

发明人： Teresita M. Bellido ,  G. David Roodman ,  Jesus Delgado-Calle ,  Robert K. Boeckman ,  Frank H. Ebetino

IPC分类号： A61K31/664 ,  A61K38/29 ,  C07F9/38 ,  A61K45/06 ,  A61P35/00

CPC分类号： A61K31/664 ,  A61K38/29 ,  A61K45/06 ,  A61P35/00 ,  C07F9/3886

摘要： Various aspects and embodiments disclosed herein relate generally to the modelling, treatment, reducing resistence to the treatment, prevention, and diagnosis of diseases/symptoms induced by multiple myeloma. Embodiments include methods of treating a bone related disease, comprising the steps of: administering to a subject at least one therapeutically effective dose of a compound disclosed herein.

公开(公告)号：US20230321199A1

公开(公告)日：2023-10-12

申请号：US18320638

申请日：2023-05-19

申请人： Radius Health, Inc.

发明人： Gary Hattersley

IPC分类号： A61K38/29 ,  A61P19/08 ,  A61P19/10 ,  A61K9/00 ,  A61K45/06

CPC分类号： A61K38/29 ,  A61P19/08 ,  A61P19/10 ,  A61K9/0019 ,  A61K45/06

摘要： Disclosed herein are PTHrP or analogues thereof, such as abaloparatide, for preventing or reducing bone fractures in subjects in need thereof, as well as methods of using PTHrP or analogues thereof to prevent or reduce bone fractures. Also disclosed are PTHrP or analogues thereof, such as abaloparatide, for increasing BMD and/or TBS in subjects in need thereof, as well as methods of using PTHrP or analogues thereof to increase BMD and/or TBS.